These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. JAK2V617F-dependent down regulation of SHP-1 expression participates in the selection of myeloproliferative neoplasm cells in the presence of TGF-β. Aoun C; Maslah N; Ganesan S; Salomao N; Gendron R; Awan Toor S; Letort G; Gou P; Bonnamy M; Parietti V; Kiladjian JJ; Giraudier S; Cassinat B J Cell Mol Med; 2024 Oct; 28(20):e70138. PubMed ID: 39431551 [TBL] [Abstract][Full Text] [Related]
9. Increased levels of NETosis in myeloproliferative neoplasms are not linked to thrombotic events. Schmidt S; Daniliants D; Hiller E; Gunsilius E; Wolf D; Feistritzer C Blood Adv; 2021 Sep; 5(18):3515-3527. PubMed ID: 34464975 [TBL] [Abstract][Full Text] [Related]
10. Hemodynamic force triggers rapid NETosis within sterile thrombotic occlusions. Yu X; Tan J; Diamond SL J Thromb Haemost; 2018 Feb; 16(2):316-329. PubMed ID: 29156107 [TBL] [Abstract][Full Text] [Related]
11. Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm. Castiglione M; Jiang YP; Mazzeo C; Lee S; Chen JS; Kaushansky K; Yin W; Lin RZ; Zheng H; Zhan H J Thromb Haemost; 2020 Dec; 18(12):3359-3370. PubMed ID: 32920974 [TBL] [Abstract][Full Text] [Related]
12. Thrombosis among 1537 patients with JAK2 Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332 [TBL] [Abstract][Full Text] [Related]
13. Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. Lamrani L; Lacout C; Ollivier V; Denis CV; Gardiner E; Ho Tin Noe B; Vainchenker W; Villeval JL; Jandrot-Perrus M Blood; 2014 Aug; 124(7):1136-45. PubMed ID: 24951423 [TBL] [Abstract][Full Text] [Related]
14. Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells. Mansier O; Kilani B; Guitart AV; Guy A; Gourdou-Latyszenok V; Marty C; Parrens M; Plo I; Vainchenker W; James C Blood; 2019 Dec; 134(26):2383-2387. PubMed ID: 31697834 [TBL] [Abstract][Full Text] [Related]
15. SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm. Yang Y; Abbas S; Sayem MA; Dutta A; Mohi G Blood Cancer J; 2023 Nov; 13(1):171. PubMed ID: 38012156 [TBL] [Abstract][Full Text] [Related]